Compare Bristol-Myers Squibb Co (BMY) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Qurate Retail Inc Series A — how do they compare? Bristol-Myers Squibb Co trades at $58.51 (market cap $116.30B), while Qurate Retail Inc Series A trades at $0.1 (market cap $1.05M). The key difference: Bristol-Myers Squibb Co is far larger — about 110761.9× Qurate Retail Inc Series A's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| BMY | QVCAQ | |
|---|---|---|
Market Cap | $116.30B | $1.05M |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $15.03 |
52-Week Low | $42.60 | $0.07 |
Enterprise Value | $152.24B | $4.74B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QVCAQ trades at $0.082, down 9.99% today, with a bearish technical outlook showing 13 sell signals versus 3 buy signals. Fundamentally, the company reported a net loss of $2.44 billion in 2025 on $9.23 billion revenue, with negative shareholder equity of $971 million and concerning debt-to-asset ratio of 77.57%. Recent earnings show volatility with one beat and three misses in the last four quarters.
The stock faces significant headwinds from persistent losses, negative equity, and high leverage. While QVC's recent brand celebration shows ongoing operations, the financial deterioration and bearish technical indicators suggest caution. Recovery depends on sustainable profitability improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
